Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity

By afschroeder • October 13, 2025

Li YR, Shen X, Zhu Y, Li Z, Hon R, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, Lin D, Sargsyan K, Yuan Y, Yang L. Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. J Hematol Oncol. 2025 Oct 13;18(1):86. doi: 10.1186/s13045-025-01736-9. PMID: 41077583.

Tags: allogeneic CAR-NKT cells, Allogeneic cell therapy, allorejection, Cedars Sinai DoM, CRISPR-Cas9 gene editing, Hematology/Oncology, HLA ablation, Mesothelin-targeting CAR (MCAR), Metastatic model, Multiple tumor targeting mechanism, Off-the-shelf, Orthotopic model, Potent antitumor activity, Publications, Triple-negative breast cancer (TNBC), tumor microenvironment (TME), Tumor-associated macrophage (TAM)

Temporal Changes in Quality of Life in Patients with alcohol-associated Acute Pancreatitis

Kadi T, Zheng Y, Papachristou GI, Buxbaum JL, Pisegna JR, Pandol SJ, Adeniran E, Rothenberger S, Jeon CY, Yadav D. Temporal Changes in Quality of[...]

Uptake, Geographic Access, and Outcomes of Transcatheter Mitral Valve Repair in the United States

Watanabe A, Ueyama HA, Miyamoto Y, Gotanda H, Kaneko T, Latib A, Kolte D, Baron SJ, Secemsky E, Laham RJ, Tsugawa Y, Kuno T. Uptake,[...]

Ferumoxytol-Enhanced Cardiovascular Magnetic Resonance Imaging: Applications and Technical Advances

Nguyen KL, Loke YH, Li JM, Bedayat A, Yang HJ, Xie Y, Christodoulou AG, Li D, Zhong X, Finn JP. Ferumoxytol-Enhanced Cardiovascular Magnetic Resonance Imaging:[...]